Your browser doesn't support javascript.
loading
Glial fibrillary acidic protein, neurofilament light, matrix metalloprotease 3 and fatty acid binding protein 4 as non-invasive brain tumor biomarkers.
Ghorbani, Atefeh; Chatanaka, Miyo K; Avery, Lisa M; Wang, Mingyue; Brown, Jermaine; Cohen, Rachel; Gorham, Taron; Misaghian, Salvia; Padmanabhan, Nikhil; Romero, Daniel; Stengelin, Martin; Mathew, Anu; Sigal, George; Wohlstadter, Jacob; Horbinski, Craig; McCortney, Katy; Xu, Wei; Zadeh, Gelareh; Mansouri, Alireza; Yousef, George M; Diamandis, Eleftherios P; Prassas, Ioannis.
Afiliación
  • Ghorbani A; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.
  • Chatanaka MK; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.
  • Avery LM; Biostatistics Division, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.
  • Wang M; Department of Biostatistics, The Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
  • Brown J; Meso Scale Diagnostics, LLC., Rockville, MD, USA.
  • Cohen R; Meso Scale Diagnostics, LLC., Rockville, MD, USA.
  • Gorham T; Meso Scale Diagnostics, LLC., Rockville, MD, USA.
  • Misaghian S; Meso Scale Diagnostics, LLC., Rockville, MD, USA.
  • Padmanabhan N; Meso Scale Diagnostics, LLC., Rockville, MD, USA.
  • Romero D; Meso Scale Diagnostics, LLC., Rockville, MD, USA.
  • Stengelin M; Meso Scale Diagnostics, LLC., Rockville, MD, USA.
  • Mathew A; Meso Scale Diagnostics, LLC., Rockville, MD, USA.
  • Sigal G; Meso Scale Diagnostics, LLC., Rockville, MD, USA.
  • Wohlstadter J; Meso Scale Diagnostics, LLC., Rockville, MD, USA.
  • Horbinski C; Meso Scale Diagnostics, LLC., Rockville, MD, USA.
  • McCortney K; Feinberg School of Medicine, Northwestern Medicine, Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.
  • Xu W; Feinberg School of Medicine, Northwestern Medicine, Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.
  • Zadeh G; Biostatistics Division, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.
  • Mansouri A; Department of Biostatistics, The Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
  • Yousef GM; MacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, ON, Canada.
  • Diamandis EP; Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, ON, Canada.
  • Prassas I; Department of Neurosurgery, Hershey Medical Center, Hershey, PA, USA.
Clin Proteomics ; 21(1): 41, 2024 Jun 15.
Article en En | MEDLINE | ID: mdl-38879494
ABSTRACT

BACKGROUND:

Gliomas are aggressive malignant tumors, with poor prognosis. There is an unmet need for the discovery of new, non-invasive biomarkers for differential diagnosis, prognosis, and management of brain tumors. Our objective is to validate four plasma biomarkers - glial fibrillary acidic protein (GFAP), neurofilament light (NEFL), matrix metalloprotease 3 (MMP3) and fatty acid binding protein 4 (FABP4) - and compare them with established brain tumor molecular markers and survival.

METHODS:

Our cohort consisted of patients with benign and malignant brain tumors (GBM = 77, Astrocytomas = 26, Oligodendrogliomas = 23, Secondary tumors = 35, Meningiomas = 70, Schwannomas = 15, Pituitary adenomas = 15, Normal individuals = 30). For measurements, we used ultrasensitive electrochemiluminescence multiplexed immunoassays.

RESULTS:

High plasma GFAP concentration was associated with GBM, low GFAP and high FABP4 were associated with meningiomas, and low GFAP and low FABP4 were associated with astrocytomas and oligodendrogliomas. NEFL was associated with progression of disease. Several prognostic genetic alterations were significantly associated with all plasma biomarker levels. We found no independent associations between plasma GFAP, NEFL, FABP4 and MMP3, and overall survival. The candidate biomarkers could not reliably discriminate GBM from primary or secondary CNS lymphomas.

CONCLUSIONS:

GFAP, NEFL, FABP4 and MMP3 are useful for differential diagnosis and prognosis, and are associated with molecular changes in gliomas.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Clin Proteomics Año: 2024 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Clin Proteomics Año: 2024 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Reino Unido